Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Bull Exp Biol Med ; 136(1): 59-61, 2003 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-14534612

RESUMO

Preincubation of rat hippocampal slices with 0.05-0.5 microM pyroglutamylasparagine amide improved characteristics of long-term potentiation of focal responses in the synaptic system of Schaffer collaterals-CA1 field pyramids facilitating LTP development and increasing its amplitude and duration. Presumably, the positive modulation of plastic characteristics of synaptic transmission in the hippocampusis is responsible for facilitation of learning and memory induced by pyroglutamylasparagine.


Assuntos
Amidas/farmacologia , Dipeptídeos/farmacologia , Hipocampo/efeitos dos fármacos , Transmissão Sináptica , Animais , Hipocampo/metabolismo , Potenciação de Longa Duração , Masculino , Ácido Pirrolidonocarboxílico/análogos & derivados , Ratos , Ratos Wistar , Sinapses/efeitos dos fármacos , Fatores de Tempo
3.
Biull Eksp Biol Med ; 110(12): 602-4, 1990 Dec.
Artigo em Russo | MEDLINE | ID: mdl-1964611

RESUMO

The tetanic stimulation of the Schaffer collaterals (SC) in rat hippocamp slices after 6 hrs in vitro conditions did not produce long-term potentiation (LTP) of the field response amplitude in the CA1 pyramidal cell layer. In contrast, LTP after the late tetanization was well preserved in the slices that were perfused for 20 minutes with 0.5 mkM L-pGlu-D-Ala-NH2 (PGAA) after 4-4.5 hrs in vitro. There were no significant reactivity changes during the perfusion of the slices with this drug concentration. Two other drugs with nootropic activity, piracetam (100 mkM) and gamma-hydroxybutyrate (100 mkM, Na-salt) did not prevent the disappearance of LTP in the late period in vitro, while enhanced the reactivity during perfusion period. The maintenance of the plastic properties of the SC-CA1 synaptic transmission under the influence of PGAA is thought to be the result of some specific interaction of the drug with LTP induction mechanisms. LTP damaged in the late period in vitro might be a new model of memory disturbances and this model can turn out to be useful for the comparative estimation of the effectiveness of the drugs with proposed nootropic activity and for the analysis of the possible mechanisms of their action.


Assuntos
Dipeptídeos/farmacologia , Hipocampo/efeitos dos fármacos , Sinapses/efeitos dos fármacos , Transmissão Sináptica/efeitos dos fármacos , Animais , Técnicas In Vitro , Masculino , Piracetam/farmacologia , Ácido Pirrolidonocarboxílico/análogos & derivados , Ratos , Ratos Endogâmicos , Oxibato de Sódio/farmacologia , Fatores de Tempo
4.
Biull Eksp Biol Med ; 108(10): 449-52, 1989 Oct.
Artigo em Russo | MEDLINE | ID: mdl-2557101

RESUMO

The effects of amiridin (9-amino-2,3,5,6,7,8-hexahydro-IH-cyclopenta(b) quinoline) and tacrine (1,2,3,4-tetrahydro-9-aminoacridine) on Schaffer collaterals--CAI field potentials were compared in rat hippocampal slice preparations. Similar dose-dependent increase in pop-spike amplitude was observed during slice perfusion with low concentrations of amiridin (5-50 microM) or tacrine (0.5-10 microM). This facilitation was not always fully reversible. The effect was accompanied by slight decrease in pop-EPSP amplitude suggesting membrane depolarization as a possible mechanism of pop-spike facilitation. Further increase in drug concentrations led to the depression and full blockade of pop-spike, that was associated with significant decrease in the pop-EPSP and fiber potential amplitudes. In contrast structurally related 4-aminopyridine evoked dose-dependent increase in both pop-EPSP and pop-spike amplitudes with all the concentrations tested (0.05-1000 microM), this facilitation was transformed into epileptiform response with 4-aminopyridine concentration about 500 microM. Possible mechanisms of drug actions on hippocampal neuron reactivity are discussed. It is suggested that amiridin might turn to be as effective as tacrine in symptomatic treatment of Alzheimer disease.


Assuntos
Aminoacridinas/farmacologia , Aminoquinolinas/farmacologia , Inibidores da Colinesterase , Hipocampo/efeitos dos fármacos , Neurônios/efeitos dos fármacos , Tacrina/farmacologia , 4-Aminopiridina/administração & dosagem , 4-Aminopiridina/farmacologia , Doença de Alzheimer/tratamento farmacológico , Aminoquinolinas/administração & dosagem , Aminoquinolinas/uso terapêutico , Animais , Relação Dose-Resposta a Droga , Técnicas In Vitro , Ratos , Ratos Endogâmicos , Tacrina/administração & dosagem , Tacrina/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...